CA2209172A1 - Murine monoclonal anti-idiotype antibody 3h1 - Google Patents

Murine monoclonal anti-idiotype antibody 3h1

Info

Publication number
CA2209172A1
CA2209172A1 CA002209172A CA2209172A CA2209172A1 CA 2209172 A1 CA2209172 A1 CA 2209172A1 CA 002209172 A CA002209172 A CA 002209172A CA 2209172 A CA2209172 A CA 2209172A CA 2209172 A1 CA2209172 A1 CA 2209172A1
Authority
CA
Canada
Prior art keywords
monoclonal anti
idiotype antibody
cea
murine monoclonal
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002209172A
Other languages
French (fr)
Other versions
CA2209172C (en
Inventor
Malaya Chatterjee
Heinz Kohler
Sunil K. Chatterjee
Kenneth A. Foon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kentucky
Original Assignee
University Of Kentucky
Malaya Chatterjee
Heinz Kohler
Sunil K. Chatterjee
Kenneth A. Foon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Kentucky, Malaya Chatterjee, Heinz Kohler, Sunil K. Chatterjee, Kenneth A. Foon filed Critical University Of Kentucky
Publication of CA2209172A1 publication Critical patent/CA2209172A1/en
Application granted granted Critical
Publication of CA2209172C publication Critical patent/CA2209172C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus

Abstract

The present invention provides a monoclonal anti-idiotype antibody 3H1 that escapes immune tolerance and elicits a specific immune response to CEA in mice, rabbits, monkeys, and patients with advanced CEA-associated disease. This invention also provides compositions which can be used in the detection or treatment of CEA-associated tumors mimics a specific epitope on carcinoembryonic antigen and a hybridoma that produces 3H1.
CA002209172A 1994-12-28 1995-12-28 Murine monoclonal anti-idiotype antibody 3h1 Expired - Fee Related CA2209172C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36548494A 1994-12-28 1994-12-28
US08/365,484 1994-12-28
PCT/US1995/017105 WO1996020219A2 (en) 1994-12-28 1995-12-28 Murine monoclonal anti-idiotype antibody 3h1

Publications (2)

Publication Number Publication Date
CA2209172A1 true CA2209172A1 (en) 1996-07-04
CA2209172C CA2209172C (en) 2007-04-10

Family

ID=23439088

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002209172A Expired - Fee Related CA2209172C (en) 1994-12-28 1995-12-28 Murine monoclonal anti-idiotype antibody 3h1
CA2209360A Expired - Fee Related CA2209360C (en) 1994-12-28 1995-12-28 Recombinant monoclonal anti-idiotype antibody 3h1 sequences relating to human carcinoembryonic antigen

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2209360A Expired - Fee Related CA2209360C (en) 1994-12-28 1995-12-28 Recombinant monoclonal anti-idiotype antibody 3h1 sequences relating to human carcinoembryonic antigen

Country Status (12)

Country Link
US (3) US7090842B1 (en)
EP (3) EP1298144A3 (en)
JP (2) JPH11500607A (en)
AT (2) ATE237687T1 (en)
AU (2) AU717779C (en)
CA (2) CA2209172C (en)
DE (2) DE69530107T2 (en)
DK (2) DK0796280T3 (en)
ES (2) ES2196098T3 (en)
MX (2) MX9704897A (en)
PT (2) PT796280E (en)
WO (2) WO1996020219A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11500607A (en) * 1994-12-28 1999-01-19 ユニバーシティ オブ ケンタッキー Mouse monoclonal anti-idiotype antibody 3H1
US20020041872A1 (en) 1996-04-12 2002-04-11 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6235280B1 (en) * 1996-04-12 2001-05-22 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6241985B1 (en) * 1996-05-15 2001-06-05 Altarex Corp. Method and composition for reconforming multi-epitopic antigens to initiate an immune response
US20080220012A1 (en) * 1996-05-15 2008-09-11 Ragupathy Madiyalakan Therapeutic Compositions that alter the immune response
US7318921B2 (en) * 1996-05-15 2008-01-15 Altarex Medical Corp. Therapeutic compositions that alter the immune response
US20020098190A1 (en) * 1997-06-13 2002-07-25 Malaya Chatterjee Compositions and methods for treating tumors bearing HMFG and CEA antigens
CA2295375A1 (en) * 1997-07-08 1999-01-21 Novopharm Biotech Inc. Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US7569674B2 (en) 1998-05-04 2009-08-04 Innexus Biotechnology International Limited Autophilic antibodies
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
AT409086B (en) * 1999-11-16 2002-05-27 Igeneon Krebs Immuntherapie NEW USE OF ANTIBODIES AS VACCINE
US6774209B1 (en) * 2000-04-03 2004-08-10 Dyax Corp. Binding peptides for carcinoembryonic antigen (CEA)
US8101200B2 (en) 2000-04-13 2012-01-24 Angiotech Biocoatings, Inc. Targeted therapeutic agent release devices and methods of making and using the same
US20020139628A1 (en) * 2001-03-30 2002-10-03 Wen-Chen Chang Retractable handle assembly
US8029803B2 (en) * 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
AT500650B1 (en) * 2003-04-17 2009-11-15 Altropus Gmbh IMMUNOGENIC RECOMBINANT ANTIBODY
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
EP1778461A4 (en) * 2004-08-05 2011-05-04 R & D Green Materials Llc Low temperature molding process for making solid biodegradable articles
EP1828771A2 (en) * 2004-11-24 2007-09-05 Health Research, Inc. Method for identifying and designing immunogenic peptides
CN101300355A (en) * 2005-10-13 2008-11-05 威瑞克斯医药公司 Chimeric antigen containing hepatitis c virus polypeptide and Fc fragment for eliciting an immune response
EP1999153B1 (en) * 2006-03-29 2014-04-23 King's College London Agonist antibodies against tshr
TWI434855B (en) * 2006-11-21 2014-04-21 Hoffmann La Roche Conjugate and its use as a standard in an immunoassay
AU2008323811B8 (en) * 2007-11-08 2014-09-18 Precision Biologics, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
US8093018B2 (en) * 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
WO2011056590A1 (en) 2009-10-26 2011-05-12 Prometheus Laboratories Inc. Assays for the detection of anti-tnf drugs and autoantibodies
CA2815026C (en) 2010-10-18 2018-11-20 Nestec S.A. Methods for determining anti-drug antibody isotypes
MX343324B (en) 2011-07-06 2016-11-01 Nestec Sa Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha.
MA40094B1 (en) * 2014-08-06 2022-05-31 Univ Miami Interleukin-2/interleukin-2 alpha receptor fusion proteins and methods of use
CA2969609C (en) 2014-12-05 2023-02-28 Nestec S.A. Indirect homogeneous mobility shift assays for the detection of biologics in patient samples
EP3774861A1 (en) 2018-03-28 2021-02-17 Bristol-Myers Squibb Company Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996345A (en) * 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
JPS54140710A (en) * 1978-03-10 1979-11-01 Mitsui Toatsu Chem Inc Anti-tumor substance and its preparation
JPS56145222A (en) * 1980-04-28 1981-11-11 Toshiyuki Hamaoka Improved antibody and its preparation
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4436728A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
DE3479289D1 (en) 1983-11-07 1989-09-14 Wistar Inst Immune response to tumours and viruses induced by anti-idiotype antibodies
US5053224A (en) 1983-11-07 1991-10-01 Hilary Koprowski Induction of antibody response to solid tumors with anti-idiotype antibodies
US5180814A (en) * 1984-01-31 1993-01-19 Akzo N.V. Tumor specific monoclonal antibodies
US4828991A (en) * 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US5106738A (en) 1984-01-31 1992-04-21 Akzo Nv Tumor specific monoclonal antibodies
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US5160723A (en) * 1985-04-19 1992-11-03 Sloan-Kettering Institute For Cancer Research Method of imaging colorectal carcinoma lesion and composition for use therein
GB2202017A (en) * 1987-03-07 1988-09-14 Alvan Michael Judson Anti-lock electric braking
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
JP2517343B2 (en) * 1988-01-26 1996-07-24 富士写真フイルム株式会社 Photothermographic material
JPH01207920A (en) 1988-02-16 1989-08-21 Oki Electric Ind Co Ltd Manufacture of inp semiconductor thin film
GB8812137D0 (en) 1988-05-23 1988-06-29 Imp Cancer Res Tech Antibodies
US5183756A (en) * 1988-08-19 1993-02-02 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibody (D612) having selective reactivity for gastrointestinal caricinomas and method for employing the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5407684A (en) 1988-12-30 1995-04-18 Virginia Commonwealth University Use of DHEA as a medicinal
US5077284A (en) * 1988-12-30 1991-12-31 Loria Roger M Use of dehydroepiandrosterone to improve immune response
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5244801A (en) * 1989-12-28 1993-09-14 Martin Tobi Process for producing monoclonal antibodies which specifically bind to benign colonic adenomatous polyps of human origin and hybridomas and monoclonal antibodies produced by said process
ATE149841T1 (en) 1990-01-26 1997-03-15 Immunomedics Inc VACCINES AGAINST CANCER AND INFECTIOUS DISEASES
US5200316A (en) * 1990-02-15 1993-04-06 Miles Inc. Immunoassay methods using noncross reactive cea gene family members antibodies
WO1991016924A1 (en) 1990-05-10 1991-11-14 The Dana-Farber Cancer Institute Enhancing the association of exogenous peptides with class i mhc molecules on immune system cells
US5608039A (en) * 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
AU2690192A (en) 1991-09-19 1993-04-27 Lionel A. Manson Tumor immunotherapy utilizing a method of overcoming the resistance of a progressively growing tumor
US5227471A (en) 1992-01-30 1993-07-13 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Monoclonal antibody PD41 that binds to a prostate mucin antigen that is expressed in human prostatic carcinoma
EP0666761A4 (en) 1992-08-31 1996-07-17 Jenner Technologies Stimulation of an antitumor t-cell response using anti-idiotypic antibodies.
JPH11500607A (en) * 1994-12-28 1999-01-19 ユニバーシティ オブ ケンタッキー Mouse monoclonal anti-idiotype antibody 3H1

Also Published As

Publication number Publication date
DK0800578T3 (en) 2003-08-11
EP0796280B1 (en) 2003-03-26
EP0796280A2 (en) 1997-09-24
WO1996020219A2 (en) 1996-07-04
AU704829B2 (en) 1999-05-06
ATE235514T1 (en) 2003-04-15
DE69530107T2 (en) 2003-10-16
EP0800578B1 (en) 2003-04-16
ATE237687T1 (en) 2003-05-15
ES2196098T3 (en) 2003-12-16
AU4649896A (en) 1996-07-19
MX9704898A (en) 1998-06-28
DE69530107D1 (en) 2003-04-30
MX9704897A (en) 1998-06-28
EP0800578A2 (en) 1997-10-15
CA2209172C (en) 2007-04-10
DK0796280T3 (en) 2003-04-22
CA2209360C (en) 2010-07-06
JPH10511846A (en) 1998-11-17
AU717779B2 (en) 2000-03-30
EP1298144A2 (en) 2003-04-02
PT796280E (en) 2003-08-29
AU717779C (en) 2002-12-05
DE69530415T2 (en) 2004-02-12
WO1996020277A2 (en) 1996-07-04
WO1996020277A3 (en) 1996-09-06
DE69530415D1 (en) 2003-05-22
AU4692796A (en) 1996-07-19
US20010047083A1 (en) 2001-11-29
WO1996020219A3 (en) 1996-09-06
CA2209360A1 (en) 1996-07-04
EP1298144A3 (en) 2006-05-31
US5977315A (en) 1999-11-02
PT800578E (en) 2003-09-30
US7090842B1 (en) 2006-08-15
JPH11500607A (en) 1999-01-19
ES2197217T3 (en) 2004-01-01

Similar Documents

Publication Publication Date Title
CA2209172A1 (en) Murine monoclonal anti-idiotype antibody 3h1
DE3574730D1 (en) MONOCLONAL ANTIBODY AGAINST A HUMAN TUMOR CARCINOMA ASSOCIATED ANTIQUE.
AU7566991A (en) Monoclonal antibody and immunoconjugates for the treatment and detection of b cell disorders
ES8609731A1 (en) Sialylated lewis X epitope, antibodies and diagnosis.
AU5414996A (en) Monoclonal antibody 1a7 and use for the treatment of melanoma and small cell carcinoma
EP0362332A4 (en) Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses
EP0597829A4 (en) Novel monoclonal antibody to novel antigen associated with human tumors.
DE3783277T2 (en) MONOCLONAL ANTIBODY AGAINST HUMAN LUNG CARCINOMA.
CA2239799A1 (en) Murine monoclonal anti-idiotype antibody 11d10 and methods of use thereof
CA2093928A1 (en) Monoclonal antibodies for detection and treatment of cancer
OA08485A (en) Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas.
EP0672253A4 (en) Carcinoma associated antigen (sk1) monoclonal antibodies against sk1, methods of producing these antibodies and use therfor.
DE3889062T2 (en) Monoclonal antibody against human BCDF.
ITRM920457A0 (en) MONOCLONAL ANTIBODIES THAT RECOGNIZE AN EPITOPE OF THE HUMAN P-GLYCOPROTEIN.
EP0160446A3 (en) Breast tumor-associated antigen and monoclonal antibodies specific thereto
NZ228837A (en) Tumour associated antigen and the monoclonal antibody reactive with it useful in diagnosing and treating cancer
IE880976L (en) Human tumour-associated antigen
NO972522L (en) Monoclonal antibodies with immunosuppressive activity
EP0297930A3 (en) Monoclonal antibodies
MX9202642A (en) MONOCLONAL ANTIBODIES AND ANTIGEN FOR HUMAN MELANOMA.
EP0446763A3 (en) Antigen for producing anti-idiotype antibody, anti-idiotype antibody and method for producing the anti-idiotype antibody
AU9161991A (en) Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses
AU6162794A (en) Carcinoma associated antigen (ng1) monoclonal antibodies against ng1, methods of producing these antibodies and use therefor
IL94304A0 (en) Novel tumor-associated antigen,antibodies,compositions and uses therefor
IT8183309A0 (en) RING-SHAPED METALLIC CONTAINER ENTIRELY OBTAINED FROM THE SAME BODY AND RELATED PROCESSING PROCEDURE.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20121228